Opdivo (nivolumab) in combination with Yervoy (ipilimumab) shows promising results
Bristol-Myers Squibb announced follow-up data evaluating Opdivo (nivolumab) monotherapy and Opdivo in combination with Yervoy (ipilimumab) in patients with platinum-pretreated mUC. Results showed patients who received the combination of Opdivo plus Yervoy experienced a higher ORR. October 20, 2018